A Double-Blind, Randomized, Crossover Comparison Between Single-Dose and Double-Dose Immediate-Release Oral Morphine at Bedtime in Cancer Patients

Journal of Pain and Symptom Management

Volumn 37, Issue 1, 2009, Pages 68-76

  Dale, Ola ^a,b   Piribauer, Maria ^a   Kaasa, Stein ^a,b   Moksnes, Kristin ^a   Knobel, Heidi ^a,b   Klepstad, Pål ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

bedtime; Double dose; drug guidelines; morphine; morphine 6 glucuronide; pharmacokinetics

Indexed keywords

MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE; OXYCODONE; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MALE; NAUSEA; NIGHT SLEEP; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; XEROSTOMIA;

ADMINISTRATION, ORAL; AGED; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 57849095722     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2007.12.016     Document Type: Article

References (21)

1. Ripamonti C., and Dickerson E.D. Strategies for the treatment of cancer pain in the new millennium. Drugs 61 7 (2001) 955-977
2. Hanks G.W., Conno F., Cherny N., et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84 5 (2001) 587-593
3. Todd J., Rees E., Gwilliam B., and Davies A. An assessment of the efficacy and tolerability of a 'double dose' of normal-release morphine sulphate at bedtime. Palliat Med 16 6 (2002) 507-512
4. Klepstad P., Kaasa S., Jystad A., Hval B., and Borchgrevink P.C. Immediate- or sustained-release morphine for dose finding during start of morphine to cancer patients: a randomized, double-blind trial. Pain 101 1-2 (2003) 193-198
5. Serlin R.C., Mendoza T.R., Nakamura Y., Edwards K.R., and Cleeland C.S. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61 2 (1995) 277-284
6. Daut R.L., Cleeland C.S., and Flanery R.C. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 17 2 (1983) 197-210
7. Klepstad P., Loge J.H., Borchgrevink P.C., Mendoza T.R., Cleeland C.S., and Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage 24 5 (2002) 517-525
8. Bruera E., Macmillan K., Hanson J., and MacDonald R.N. The Edmonton staging system for cancer pain: preliminary report. Pain 37 2 (1989) 203-209
9. Karnofsky D.A., Abelmann W.H., Craver L.F., and Burchenal J.H. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1 (1948) 634-656
10. Tyrefors N., Hyllbrant B., Ekman L., Johansson M., and Langstrom B. Determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human serum by solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionisation. J Chromatogr A 729 1-2 (1996) 279-285
11. Kvalsvik O., Borchgrevink P.C., Hagen L., and Dale O. Randomized, double-blind, placebo-controlled study of the effect of rectal paracetamol on morphine consumption after abdominal hysterectomy. Acta Anaesthesiol Scand 47 4 (2003) 451-456
12. Farrar J.T., Young Jr. J.P., LaMoreaux L., Werth J.L., and Poole R.M. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94 2 (2001) 149-158
13. Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 29 5 Suppl (2005) S90-S103
14. Bjorkman S., Akeson J., Helfer M., Fyge A., and Gustafsson L.L. Cerebral uptake of morphine in the pig calculated from arterio-venous plasma concentration gradients: an alternative to tissue microdialysis. Life Sci 57 25 (1995) 2335-2345
15. Portenoy R.K., Thaler H.T., Inturrisi C.E., Friedlander-Klar H., and Foley K.M. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther 51 4 (1992) 422-431
16. Klepstad P., Kaasa S., and Borchgrevink P.C. Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine. Eur J Clin Pharmacol 55 10 (2000) 713-719
17. Skarke C., Darimont J., Schmidt H., Geisslinger G., and Lotsch J. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 73 1 (2003) 107-121
18. Hanna M.H., Peat S.J., Woodham M., Knibb A., and Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth 64 5 (1990) 547-550
19. Klepstad P., Kaasa S., Cherny N., Hanks G., and De Conno F. Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 19 6 (2005) 477-484
20. Vijayaram S., Ramamani P.V., Chandrashekhar N.S., et al. Continuing care for cancer pain relief with oral morphine solution. One-year experience in a regional cancer center. Cancer 66 7 (1990) 1590-1595
21. Holtan A., Aass N., Nordoy T., et al. Prevalence of pain in hospitalised cancer patients in Norway: a national survey. Palliat Med 21 1 (2007) 7-13